Latest Us Market News

Origin Energy has refined its FY25 earnings forecast, buoyed by strong wholesale performance but tempered by Octopus Energy's UK weather-related losses. Despite setbacks, Octopus continues to expand its retail footprint.

3P Learning forecasts steady revenue for FY25 but anticipates a significant 20% uplift in underlying EBITDA and a stronger net cash position, driven by strategic product expansions.

Fintech Chain Limited has applied to delist from the ASX, citing low valuation, poor liquidity, and high costs, aiming to unlock growth capital in China and the US.

Smart Parking Limited reports robust H1 FY25 growth driven by a strategic US acquisition and expanding global footprint, underpinned by proprietary AI technology.

Echo IQ’s application for a key US procedural code was rejected but the company plans a swift resubmission, maintaining confidence in its US commercial rollout.

Adherium Limited has locked in $900,000 through convertible notes to fund the expansion of its Hailie® Smartinhaler® platform in the US, pending shareholder approval at the upcoming AGM.

HeraMED faces a setback as Broward Health discontinues its HeraCARE platform amid Medicaid funding cuts, prompting a strategic pivot with new leadership and partnerships to accelerate US growth.

Lumos Diagnostics has secured Medicare reimbursement for its FebriDx test from a fifth contractor, covering more than 70% of US Medicare payments and advancing its commercial reach.

International Graphite Limited has received encouraging feedback from the U.S. Department of Defense on its proposal for up to US$7.5 million in funding to advance its graphite mine-to-market strategy, potentially securing a vital supply chain from Western Australia to the U.S.

Almonty Industries reports steady tungsten market conditions and completes key financing for its Sangdong Mine, while posting a $34.6 million net loss in Q1 2025. The company advances its US Domestication and plans to restart Los Santos Mine in 2026.

HITIQ Limited has announced a non-renounceable entitlement offer to raise up to $2.92 million, supported by partial underwriting from GBA Capital and accompanied by new options issuance. The capital raise aims to fund expansion, product development, and operational growth.

Lumos Diagnostics has secured its largest single US purchase order for its rapid respiratory test FebriDx, signaling growing adoption in American healthcare settings.